For example, a soluble TNF-α receptor-Fc fusion protein (TNF-TRAP, Etanercept or Enbrel) is currently in routine clinical use for the treatment of inflammatory conditions such as rheumatoid arthritis13 and a VEGFR1/VEGFR2-Fc decoy (VEGF-TRAP, Aflibercept) is approved for the treatment of wet macular degeneration under the trade name Eylea, and for metastatic colorectal cancer as Zal-TRAP12. Here, TRAF2 is linked to wet macular degeneration.